Novartis

Alkaloid (11)
Allergan (6)
Astrazeneca (7)
Basi (302)
Bayer (10)
F hoffmann la roche ltd (24)
Glaxosmithkline (15)
Novartis (22)
Pfizer (10)
Sanofi (5)

Synopsis: Domenii: Pharma: Pharma generale: Pharmaceutical industry: Novartis:

Nature Communications published the findings, emerging from a collaboration with Novartis Institutes for Biomedical Research and Emory University.

"Co-authors are Novartis chemists Rohan Beckwith, Jing He and Lawrence Hamann. The CCHF is at the forefront of a major paradigm shift in organic chemistry.

"Novartis wanted to explore whether this chemistry was robust enough to be carried out on really complex compounds like alkaloids."

"Novartis sees great potential in C-H functionalization, "Davies says.""It has been an early and enthusiastic supporter of the CCFH through collaborative research of scientists at Novartis and in CCHF academic labs

#Enzymes believed to promote cancer actually suppress tumors Upending decades-old dogma, a team of scientists at the University of California,

After supporting the development of informatics at Avantium he moved to Novartis in Switzerland to expand the company's expertise and now works with the Institute of Cancer Research in London.

Rosenberg points to a collaboration formed in August last year between June's group and the drug giant Novartis,

Led by Amy Kistler at the Novartis Institutes for Biomedical Research in Emeryville California, the team responded to an outbreak of Theiler's disease at a farm in

The research was funded by the National Science Foundation, Novartis, and the Institute for Collaborative Biotechnologies through the U s army Research Office u

#Britain Becomes First Nation to Offer Meningitis B Vaccine After Tense Novartis AG Stand-Off The United kingdom will officially become the first country in the world to offer a vaccine for meningitis B after to infants covered under its national health system,

Britain will now be able to offer Glaxo Bexsero vaccine, formerly part of Novartis AG (NVS) vaccine portfolio under its massive asset swap earlier this year.

Novartis decided not to extend a partnership with Alnylam; Roche gave up on RNAI altogether. Alnylam laid off about a quarter of its workers

Separately, a similar Novartis gene therapy trial is under way to help restore hearing in people who have become deaf through damage or disease.

Work at Novartis is advanced more, with the first patient treated last October in an early-stage clinical trial that will recruit 45 subjects in the United states,

Novartis research head Mark Fishman describes it as a'spare parts'approach to fixing ageing-related frailty.

pharmaceutical giant Novartis announced this week that it testing similar technology through a collaboration with a startup called Rani Therapeutics.

Astellas, Bayer, Boehringer ingelheim, Glaxosmithkline, Lilly, Novartis, Roche, Sanofi, Takeda, UCB, and Viiv Healthcare. Three industry groupspharmaceutical Research and Manufacturers of America (Phrma), the European Federation of Pharmaceutical industries and Associations (EFPIA),

In a statement to GEN, Novartis said it is looking into linking payment to patient outcomes

Novartis said. he majority of CML patients in the U s. pay less than $100 out of pocket per month for our CML treatments,

To that end, Novartis said, its patient assistance program provides the company medicines for free or at a reduced cost to those who can afford them,

Novartis asserted. reater attention should be paid to larger issues such as different charges for similar hospital services, costs across the complex healthcare systems and the growing complexity of our public and private

which has an exclusive partnership with Novartis (NYSE: NVS), reported the cells showed no effect on the tumors.

< Back - Next >

Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011